Trial site
Palmerston North Hospital
Palmerston North, 4414, New ZealandNot linked to an institution yet
- 10running trials
- 5closed trials
The trials here
What the 15 trials at this site are about, from their registry records.
- Phase
- Phase 311 trials
- Phase 2/32 trials
- Phase 21 trial
- Status
- Active, not recruiting9 trials
- Completed5 trials
- Recruiting1 trial
- Lead sponsor
- Pfizer4 trials
- Hoffmann-La Roche3 trials
- University of Sydney2 trials
- BeiGene1 trial
- EMD Serono Research & Development Institute, Inc.1 trial
- and 4 more
Running trials
Recruiting
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
NCT07028853· Phase 3· Pfizer· Source
Active, not recruiting
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
NCT06065748· Phase 3· Hoffmann-La Roche· Source
Recruiting
DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT04920617· Phase 2· ImmunoVaccine Technologies, Inc. (IMV Inc.)· Source
Contact: RCTS Clinical Trials Unit
Active, not recruiting
A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma
NCT04657991· Phase 3· Pfizer· Source
Active, not recruiting
Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate
NCT04136353· Phase 3· University of Sydney· Source
Active, not recruiting
A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
NCT04191499· Phase 2/3· Hoffmann-La Roche· Source
Active, not recruiting
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy
NCT03522246· Phase 3· pharmaand GmbH· Source
Active, not recruiting
A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL
NCT03336333· Phase 3· BeiGene· Source
Active, not recruiting
Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer
NCT02446444· Phase 3· University of Sydney· Source
Active, not recruiting
Radiotherapy - Adjuvant Versus Early Salvage
NCT00860652· Trans Tasman Radiation Oncology Group· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error